• Partnership to use multi-target approach for novel cancer therapies discovery
    Shahar Keinan
  • Chris Torrance

News & Views

Partnership to use multi-target approach for novel cancer therapies discovery

Jan 07 2022

UK-based biopharmaceutical company PhoreMost and US quantum computing drug design business Polaris Quantum Biotech, are combining their technologies for the search and development of next generation oncology therapies derived from targets previously considered to be undruggable.

Under the terms of the agreement the POLARISqb Tachyon™ platform will be used to scan billions of molecules from a large chemical space, seeking novel molecular drugs based on information obtained from PhoreMost’s SITESEEKER® phenotypic screening platform. It is expected that the increased power of the quantum computer will drastically shorten the drug discovery process, through the ability to perform combinatorial optimisations in minutes that would take classical supercomputers months or even years to complete.

“This collaboration is a significant milestone for POLARISqb,” said Dr. Shahar Keinan, POLARISqb CEO. “Quantum Computing technology is coming of age, allowing us to revolutionise drug discovery timelines and budgets, while improving the overall profile of the designed drugs. The experience and speed of PhoreMost’s technology is a great match to POLARISqb and we are excited to work together." 

Dr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”

More information online

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events